- Home
- BFST vs MLYS Comparison
BFST vs MLYS Comparison
Compare BFST & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- MLYS
- Stock Information
- Founded
- BFST 2006
- MLYS 2019
- Country
- BFST United States
- MLYS United States
- Employees
- BFST N/A
- MLYS N/A
- Industry
- BFST Major Banks
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- BFST Finance
- MLYS Health Care
- Exchange
- BFST Nasdaq
- MLYS Nasdaq
- Market Cap
- BFST 783.9M
- MLYS 890.6M
- IPO Year
- BFST 2018
- MLYS 2023
- Fundamental
- Price
- BFST $23.78
- MLYS $14.52
- Analyst Decision
- BFST Strong Buy
- MLYS Strong Buy
- Analyst Count
- BFST 3
- MLYS 4
- Target Price
- BFST $30.00
- MLYS $27.00
- AVG Volume (30 Days)
- BFST 95.2K
- MLYS 785.9K
- Earning Date
- BFST 07-28-2025
- MLYS 08-12-2025
- Dividend Yield
- BFST 2.35%
- MLYS N/A
- EPS Growth
- BFST 3.92
- MLYS N/A
- EPS
- BFST 2.51
- MLYS N/A
- Revenue
- BFST $291,096,000.00
- MLYS N/A
- Revenue This Year
- BFST $25.48
- MLYS N/A
- Revenue Next Year
- BFST $17.20
- MLYS N/A
- P/E Ratio
- BFST $9.46
- MLYS N/A
- Revenue Growth
- BFST 17.48
- MLYS N/A
- 52 Week Low
- BFST $20.07
- MLYS $8.24
- 52 Week High
- BFST $30.30
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- BFST 44.72
- MLYS 57.42
- Support Level
- BFST $22.62
- MLYS $12.59
- Resistance Level
- BFST $24.71
- MLYS $13.70
- Average True Range (ATR)
- BFST 0.61
- MLYS 0.75
- MACD
- BFST 0.04
- MLYS 0.11
- Stochastic Oscillator
- BFST 46.40
- MLYS 75.39
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.